Antibiotic-associated disorders of prothrombin synthesis and their probiotic correction with \textit{B. clausii} in breastfed infants

O. G. Ivanko, O. V. Solianyk

Zaporizhzhia State Medical University, Ukraine

Key words: infant, Bacillus clausii, breast feeding, decarboxy-prothrombin, blood coagulation tests, antibiotic agents.

The aim of the investigation was to study the prothrombin test and PIVKA-II serum levels changes in infants aged 1–6 month after the broad-spectrum antibiotic treatment and determine the possibility of coagulation disorders correction with the help of probiotic \textit{Bacillus clausii} strains OC, NR, T. \textit{SIN} spores capable to produce vitamin K$_{\text{r}}$.

Materials and methods. The study involved 57 convalescents after an acute respiratory infection exclusively breastfed infants aged 1 to 6 months one week after the 7-day parenteral treatment with ceftriaxone. Among them 13 children with laboratory signs of blood hypocoagulation (INR > 1.3) had received probiotic \textit{Bacillus clausii} spores in a daily dose of $2 \times 10^{9}$ CFU for 10 days. Another 13 children who had not received a probiotic made up a comparison group. Laboratory data was compared with the results of 27 healthy children of the control group. Prothrombin test parameters as a prothrombin (PT), prothrombin time (PTT), international normalized ratio (INR) and protein induced by vitamin K absence or antagonist II (PIVKA-II) were determined using the hematoletic analyzer COAGUCHEC XS and ELISA kit.

Results. It was found that after antibacterial treatment in infants PT was decreased and reached only 50 \% of the norm. At the same time, PTT and INR were increased up to 2-folds together with a significant PIVKA-II elevation, which is typical for vitamin K deficiency. The use of probiotic treatment within 10 days has contributed to normalization of prothrombin in 11 out of 13 observed infants versus 3 out of 13 in the comparison group ($\chi^2 = 7.58$ corrected by Yates, $P < 0.05$).

Conclusions. Cephalosporin administration for breastfed infants can lead them to latent vitamin K deficiency development, which is manifested by high levels of PIVKA-II and signs of hypocoagulation development revealed by prothrombin test. The \textit{Bacillus clausii} probiotic spores prescription to infants after antibiotic therapy course for 10 days normalizes the plasma prothrombin concentration while in children of the comparison group it remains lower than normal.

Zaporozhie medical journal 2018; 20 (3), 384–387


ISSN 2306-4145    http://zmj.zsmu.edu.ua

UDC: 616.15:577.152.34-02:615.33-085.37-053

Antibiotikoассоцированые поражения синтеза протромбина и их пробиотическая коррекция за помощью \textit{B. clausii} в дейт ответственном выигрышном

О. Г. Иванько, О. В. Соляник

Запорожская медицинская больница. Том 20, № 3(108), май–июнь 2018 г.

Ключевые слова: грудные дети, \textit{B. clausii}, естественное вскармливание, PIVKA-II, пробиотический тест, антибиотики.

Цель работы – изучить изменения показателей пробиотического теста и содержание в сыворотке крови PIVKA-II у грудных детей первых 6 месяцев жизни после лечения антибиотиком широкого спектра действия и определить возможность коррекции нарушенных с помощью спор пробиотических штаммов OC, NR, \textit{T. SIN Bacillus clausii}, способных вырабатывать витамин K$_{\text{r}}$.

Материалы и методы. В исследовании участвовали дети в возрасте от 1 до 6 месяцев жизни, находившиеся на исключительном грудном вскармливании с момента рождения. Через 7 дней после окончания 7-дневного курса лечения цефтриаксоном отбирали лекарство цефтриаксоном, нормализует вміст ПТ у плазмі, а в дітей групи порівняння він залишається зниженим.

Заключение. Встановлено, що після антибактеріального лікування ПТ становив 50 % від норми, ПТЧ і МНВ збільшувалися вдвічі при чималому підвищенні концентрації PIVKA-II, що характерне для дефіциту вітаміну К. Призначення пробіотика сприяло нормалізації вмісту вітаміну-К-залежного протеїну крові протромбіну в 11 із 13 немовлят, а у групі порівняння таких дітей було 3 із 13 ($\chi^2 = 7.58$ за Йейтсом, $p < 0.05$).

Висновки. Застосування цефалоспорину в дітей первших 6 місяців життя, які отримують грудне вигодовування, може привести до розвитку прихованого вітамін-К-дефіциту, що проявляється підвищенням сироваткових концентрацій недостатньо карбоксилованого протромбіну (PIVKA-II), зниженням вмісту ПТ, подовженням ПТЧ і збільшенням МНВ. Застосування пробіотичного препарату на основі спор \textit{Bacillus clausii} в добовій дозі $2 \times 10^{9}$ КУО протягом 10 днів у діях, які отримували лекарство цефтриаксоном, нормалізує вміст ПТ у плазмі, а в дітях групи порівняння він залишається зниженим.

Ключевые слова: грудные дети, \textit{B. clausii}, естественное вскармливание, PIVKA-II, пробиотический тест, антибиотики.

The study was to investigate the prothrombin test and PIVKA-II serum levels changes in infants aged 1–6 month after the broad-spectrum antibiotic treatment and determine the possibility of coagulation disorders correction with the help of probiotic \textit{Bacillus clausii} strains OC, NR, T. \textit{SIN} spores capable to produce vitamin K$_{\text{r}}$.

Materials and methods. The study involved 57 convalescents after an acute respiratory infection exclusively breastfed infants aged 1 to 6 months one week after the 7-day parenteral treatment with ceftriaxone. Among them 13 children with laboratory signs of blood hypocoagulation (INR > 1.3) had received probiotic \textit{Bacillus clausii} spores in a daily dose of $2 \times 10^{9}$ CFU for 10 days. Another 13 children who had not received a probiotic made up a comparison group. Laboratory data was compared with the results of 27 healthy children of the control group. Prothrombin test parameters as a prothrombin (PT), prothrombin time (PTT), international normalized ratio (INR) and protein induced by vitamin K absence or antagonist II (PIVKA-II) were determined using the hematoletic analyzer COAGUCHEC XS and ELISA kit.

Results. It was found that after antibacterial treatment in infants PT was decreased and reached only 50 \% of the norm. At the same time, PTT and INR were increased up to 2-folds together with a significant PIVKA-II elevation, which is typical for vitamin K deficiency. The use of probiotic treatment within 10 days has contributed to normalization of prothrombin in 11 out of 13 observed infants versus 3 out of 13 in the comparison group ($\chi^2 = 7.58$ corrected by Yates, $P < 0.05$).

Conclusions. Cephalosporin administration for breastfed infants can lead them to latent vitamin K deficiency development, which is manifested by high levels of PIVKA-II and signs of hypocoagulation development revealed by prothrombin test. The \textit{Bacillus clausii} probiotic spores prescription to infants after antibiotic therapy course for 10 days normalizes the plasma prothrombin concentration while in children of the comparison group it remains lower than normal.
Introduction

Antibiotics are able to cause a variety of side effects. There are well-known cases of diarrhea (ICD-10 A7) associated with a change in the ratio of microbial organisms inhabiting the intestine with an uncontrolled increase in a number of microbes capable to exhibit aggressive properties. It is quite obvious that some intestinal symbiotics (Bacteroides, Enterobacteriaceae and several other), that participate in B group, PP, etc., vitamins synthesis in colon can also be suffered from antibiotic depressive influences. The role of colonic microbiota in providing children and adults with vitamins K (menaquinones) is essential. The fact is that the cycle of vitamin K in newborns and infants of the first 6 months of life is characterized by instability which in its extreme clinical manifestation may be manifested by early or late neonatal hemorrhagic disease associated with vitamin K deficiency (ICD-10 P-53). In common situations the latent vitamin K deficiency is related to some ontogenetic "experienci" that counteracts the risk of pregnancy-associated disseminated intravascular coagulation, low fetal vitamin K supply, the absence of significant depot due to insufficient transport through placenta and extremely small amounts of the vitamin in breast milk unable to provide the child physiological needs. Vitamin K deficiency complications treatment after delivery overcomes by vitamin K (phyloquinone) intramuscular bolus administration in an amount of 1 mg which corresponds to 40 daily doses for infant [1]. Children who are fed with modern milk formulas get enough vitamins including vitamin K because of feeding fortification in accordance with age-related needs of children. However infants, who are exclusively breastfed after 8 days of life, fall into the risk of hypovitaminosis K again after fast elimination of the phyloquinone given to a newborn immediately after the birth as a bolus. At the same time, cases of the late hemorrhagic disease in healthy infants are relatively rare. At the age of 1 month the laboratory signs of vitamin K deficiency spontaneously disappear what can be explained by the colonic microbiota activity and its vitamin K-producing component [2]. During the following months despite the vitamin K deficiency in food persistence in the absence of additional vitamin supplementation the metabolic cycle of vitamin K is maintained only by intestinal microorganisms. Many diseases can disrupt labile balance of vitamin K supplementation in infants. Liver and intestinal diseases including colonic microbiota disturbances can cause significant impact on vitamin K synthesis, absorption and biotransformation. An unique feature of vitamin K cycle is a very rapid development of hypovitaminosis which commonly clinically manifests as bleeding. For example, the use of vitamin K antagonist warfarin can lead to blood hypocoagulation as early as the 2–3 day after administration [3]. The role of vitamin K in humans is being intensively studied. The concept of “vitamin K” combines a number of biochemical derivatives (vitamers) of 2-methyl-1, 4-naphthoquinone, which have approximately the same function. All of them are co-factors for the γ-glutamyl carboxylase enzyme which is essential for a number of plasma proteins, bone tissue, blood vessels and myocardium carboxylation by the way of replacement the carboxyl radical (Gla residue) instead of the glutamine radical (Glu residue). The classic human vitamin K-dependent protein is a prothrombin. This is one of the most important serum clotting factors (factor II) which in its posttranscriptional modification needs a carboxylation with the participation of vitamin K. The approved biochemical sign used for vitamin K deficiency evaluation is a high plasma concentration of the Glu residues of prothrombin or the PIVKA-II (protein induced by vitamin K absence or undercarboxylated prothrombin) [4]. In lack of the functionally mature Glu residue of prothrombin the signs of vitamin K-deficient hypocoagulation develop: the level of prothrombin decreases and so called prothrombin time and bleeding time get slower. Although there are some information that the commonly used prothrombin test may be dependant on a treatment with antibiotics [5], the mechanisms and clinical importance of this phenomenon have not been enough studied.

The aim

The aim of the investigation was to study the prothrombin test and PIVKA-II serum levels changes in infants aged 1–6 months after the broad-spectrum antibiotic treatment and determine the possibility of coagulation disorders correction with the help of probiotic Bacillus clausii strains OC, NR, T, SIN spores capable to produce vitamin K$_{2}$. Materials and methods

The study involved 84 children aged 1 to 6 month. There were 50 (59.5 %) boys and 34 (40.5 %) girls. All children were born at the 38–40-th week of gestation after vaginal delivery. There were 57 children-children after acute respiratory illness. In them 13 children with laboratory signs of mild thrombocytopenia (MNO > 1,3) in the course of 10 days obtained probiotics culture Bacillus clausii in the daily dose of 2 × 10$^{9}$ COE. Among these children, 11 were boys and 9 were girls. All children were included in the study and divided into two groups. The first group included 13 children who were probiotic probiotics. The second group included 13 children who were not probiotic probiotics. The study included 57 children. The group of probiotic probiotics included 13 children, the remaining 13 children were included in the control group. The prothrombin complex assay was performed using the method of the international normalisation index (INN) – the method of the international normalisation index (INN).
### Table 1. Prothrombin test and PIVKA-II values in infants received antibiotic treatment in comparison with healthy children (M ± m)

<table>
<thead>
<tr>
<th>Children groups</th>
<th>n</th>
<th>INR (un.)</th>
<th>PTT (sec)</th>
<th>PT (%)</th>
<th>PIVKA-II (Au/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treated with antibiotic</td>
<td>31</td>
<td>2.60 ± 0.80</td>
<td>53.8 ± 10.1</td>
<td>38.1 ± 5.8</td>
<td>129.6 ± 33.1</td>
</tr>
<tr>
<td>Healthy (control)</td>
<td>27</td>
<td>1.14 ± 0.13</td>
<td>24.9 ± 5.1</td>
<td>85.8 ± 9.5</td>
<td>26.9 ± 4.7</td>
</tr>
<tr>
<td>P</td>
<td></td>
<td>&lt;0.050</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

INR: the international normalized ratio; PTT: prothrombin time; PT: prothrombin; PIVKA-II: protein induced by vitamin K absence; P: the probability of statistical error.

### Table 2. Prothrombin complex values in dynamics of a 10-day length observation in infants who have received Bacillus clausii probiotic spores and in the control group

<table>
<thead>
<tr>
<th>Children groups</th>
<th>n</th>
<th>At the start</th>
<th>At the finish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment with Bacillus clausii</td>
<td>13</td>
<td>2.99 ± 0.65</td>
<td>93.7 ± 4.0</td>
</tr>
<tr>
<td>Control</td>
<td>13</td>
<td>3.08 ± 0.71</td>
<td>33.9 ± 4.6</td>
</tr>
<tr>
<td>P</td>
<td></td>
<td>&gt;0.500</td>
<td>&gt;0.500</td>
</tr>
</tbody>
</table>

INR: the international normalized ratio; PTT: prothrombin time; PT: prothrombin; P: the probability of statistical error.

#### Fig. 1. Plasma prothrombin (%) concentrations in infants in dynamics of 10-day length probiotic therapy (1) and in control (2).

1. **Prothrombin (normal limits 80–120 %)**
   - **Bacillus clausii 2 x 10 E9 CFU/day**
   - **Prothrombin (normal limits 80–120 %)**
   - **33.9 ± 6.1 (normal)**
   - **75.0 ± 4.0 (normal)**

#### Results and discussion

As it is shown in Table 1, the parameters of vitamin K-dependent procoagulant plasma proteins in breastfed infants depend significantly on the fact of cephalosporin administration.

As it follows from the data in Table 1, healthy infants aged 1–6 month achieved almost normal levels (53 %) children did not receive vitamin K, due to various reasons among which most often there were the parents’ refusals because of some fears if the child could be traumatized with an “extra” injection. The main part of the study was based on observations of 57 convalescents after an acute respiratory infection (non-severe community-acquired pneumonia) or acute otitis media one week after the 7-day length parenteral treatment with ceftriaxone at a daily dose of 50–80 mg/kg. Clinical observations were carried out in the Department of Neonatal Pathology and Early Childhood Diseases in the Pediatric Hospital № 5, Zaporizhzhia.

The hematology analyzer COAGUChEC XS (Germany) examined the capillary blood for the traditional parameters of the prothrombin complex. There were the plasma prothrombin (PT) as a percentage of the “ideal” level in the reference plasma (normal values within 80–120 %), prothrombin time (PTT) (usual limits 11–18 sec.) and international normalized ratio (INR) (0.9–1.3). The INR is a derivative parameter of the PTT in form of patient prothrombin time ratio to normal plasma prothrombin time in power of mathematical corrective units by which a laboratory standardization of the prothrombin time can be made.

Concentrations of PIVKA-II were studied in the venous blood serum. The enzyme-linked immunoassay for PIVKA-II determination was carried out with the diagnostic ANTIBODY RESEARCH PIVKA-II ELISAKit (USA) and the SirioS SEA Ca / RADIM analyzer (China) in the Central Research Laboratory of Zaporizhzhia State Medical University.

The obtained clinical and laboratory data allowed to compare the cohort of 31 children grouping in accordance to antibacterial treatment impact and the control cohort of 27 healthy children. The hypothesis whether the probiotic therapy with Bacillus clausii be capable to restore low plasma prothrombin in breastfed infants after antibiotic therapy was figured out in controlled study of two reference groups. All of them were children grouped according to elevated INR > 1.3 criterion. However, they were free from any evident signs of bleeding. In addition, children did not demonstrate diarrhea, jaundice, hypoproteinemia, AST/ALT elevation. By fixed randomization 13 patients were assigned for 10-day length probiotic therapy in a daily dose of 2 x 10^9 colonies formed units (CFU) OC, NR, T, SIN strains spores of Bacillus clausii which vegetative microorganisms are capable to produce menaquinones [6,7]. Another 13 infants corresponding to the age, sex, feeding type and laboratory values were not given probiotics. They made up a comparison group. Simultaneously all children received a standard therapy with mucolytic and vitamin D3.

Statistical processing was carried out using certified programs Statistica 6.0 (StatSoft, USA) (license No. 31415426535897).

### Prothrombin (normal limits 80–120 %)

- **Prothrombin (normal limits 80–120 %)**
- **33.8 ± 4.6 (normal)**
- **75.0 ± 4.0 (normal)**

Statistical processing was carried out using certified programs Statistica 6.0 (StatSoft, USA) (license No. 31415426535897).

### Results and discussion

As it is shown in Table 1, the parameters of vitamin K-dependent procoagulant plasma proteins in breastfed infants depend significantly on the fact of cephalosporin administration.

As it follows from the data in Table 1, healthy infants aged 1–6 month achieved almost normal levels
of prothrombin test comparable to those in adults with the exception of PTT slight prolongation. Although breast milk feeding formally unable to provide sufficient intake of vitamin K with food, healthy children shown an acceptable levels of serum Gla prothrombin (PIVKA-II) which indicates the absence of significant vitamin K-deficiency.

It means that in healthy children the intestinal microbiota can provide them with vitamin K. In turn, the microbiota is susceptible to the damage associated with antibacterial therapy exposure. In response to the ceftriaxone administration infants had laboratory signs of hypocoagulation sufficient for late hemorrhagic disease of newborns development. Thus the level of PT after the antibacterial course was only 50% of the norm, PTT and INR were increased more than 2 times with substantially increased PIVKA-II serum concentrations typical for vitamin K deficiency.

These changes should be explained by an antibiotic-associated impact on menaquinone synthesizing colonic microflora. In accordance with the background of the study, an attempt of colon microbiota therapeutic correction by the administration of Bacillus clausii probiotic strain, which vegetative forms are capable to produce menaquinones in the human large intestine, was studied. The results are shown in Table 2.

As it follows from Table 2, the prothrombin complex values in both of the clinical and control groups are characterized by a tendency toward their normalization after the antibacterial therapy discontinuing. It is explained by the intestinal microbiome ability to quantitative and qualitative self-repairing and accordingly to improvement in the availability to provide children with menaquinones. Simultaneous administration of the Bacillus clausii probiotic has promoted more complete prothrombin normalization. As it is shown in the Fig. 1, the full values of this vitamin K-dependent protein restoration in 10 days of probiotic therapy was noted in 11 out of 13 infants, while among the children of the control group there were only 3 such infants out of 13 (χ² = 7.58, corrected by Yates, P < 0.05).

Conclusions

1. Parenteral cephalosporin administration in breastfed infants aged 1–6 month can lead to a latent vitamin K-deficient state development, which is manifested by a significant PIVKA-II serum concentrations increasing, plasma prothrombin decreasing and prolongation of prothrombin time with elevation of international normalized ratio.

2. The use in infants the probiotic spores of Bacillus clausii in a daily dose of 2 × 10⁶ CFU for 10 days after antibiotic treatment restores the plasma prothrombin levels.

The prospects of further research. It would be expedient to recommend the probiotic spores of Bacillus clausii administration to infants especially who is breastfed immediately during the antibiotic therapy. A probiotic preparation, which can positively influence on the intestinal microbiota state increasing the vitamin K supplementation, should be investigated in comparison with vitamin K enteral administration in their ability to improve the plasma coagulation capacity in infants receiving exclusively breast milk.